About S&S Investment
S&S Investment is a venture capital firm founded in 2020. It is primarily based out of Seongnam-si, South Korea. As of Aug 2026, S&S Investment is an active investor, having invested in 27 companies, with 2 new investments in the last 12 months. It primarily invests in Series B round in South Korea based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and Auto Tech. Most recently it participated in the $***** Series B round of aweXome Ray Overall, S&S Investment portfolio has seen 1 unicorn, 2 IPOs and 1 acquisition including key companies like Phantom, ImmuneOncia and RIDI. A lot of funds co-invest with S&S Investment, with names like Industrial Bank of Korea sharing a substantial percentage of its portfolio. S&S Investment has team of 5 people including 5 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B & Series A
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns
Deals in last 12 months
S&S Investment's List of Top Investments
S&S Investment has a portfolio of 27 companies, one of which is a Unicorn. Their most notable investments are in MetaFines and AIMMO.Their portfolio spans across South Korea, United States and India. They have invested in Life Sciences, Enterprise Applications, Auto Tech and 16 other sectors, across stages such as Series B, Series A stages. Here is the list of top investments by S&S Investment:
1. Phantom
AI-enabled full-stack system provider for autonomous vehicles. It is an artificial intelligence company focused on developing and optimizing software stacks & sensor suites for autonomous driving while providing various levels of autonomy as end solutions. The company offers technologies for computer vision and Level-2 autonomous vehicles as well as it is developing an optimal platform & sensor suite for Level-4 autonomy in vehicles.
Key facts about Phantom
- Founded Year: 2016
- Location: Burlingame (United States)
- Stage: Acquired
- Total Funding till date: $80.2M
- Employee Count: 52 as on Jun 30, 2026
- Investors: Ford, Millennium Technology Value Partners and 12 Others
- Latest Funding Round: Series C, Feb 01, 2023, $*****
- Highlight: Acquired
2. 5C Network
Provider of an AI-powered radiology platform. It focuses in teleradiology services for diagnostics like X-rays, CT, MRI, and more, serving hospitals and doctors with rapid reporting. It offers image interpretation and reporting services to healthcare facilities. The network provides technology for radiology workflow and reporting. It supports hospitals and radiologists with tools for image analysis.
Key facts about 5C Network
- Founded Year: 2017
- Location: Bengaluru (India)
- Annual Revenue: ₹10 - ₹50 Cr as on Mar 31, 2025
- Valuation: $*****
- Stage: Series A
- Total Funding till date: $12.1M
- Employee Count: 214 as on Aug 31, 2025
- Investors: Celesta Capital, Capria and 34 Others
- Latest Funding Round: Series A, Apr 05, 2024, $*****
- Highlight: Editors' Pick
Developer of disruptive therapies for oncology and infectious diseases. It provides TAER-TAB technology which is a bispecific antibody (bsAb) platform that targets cancer cells. It also provides ViTRAP technology which is a broad-spectrum antiviral therapeutics platform.
Key facts about Pinetree Therapeutics
- Founded Year: 2019
- Location: Cambridge (United States)
- Stage: Series B
- Total Funding till date: $87.5M
- Employee Count: 42 as on Jun 30, 2026
- Investors: STIC Ventures, Smile Gate Investment and 12 Others
- Latest Funding Round: Series B, Nov 14, 2025, $*****
- Highlight: Editors' Pick
4. ImmuneOncia
Developer of monoclonal and specific antibody for cancer treatment. The company's lead antibody IMC-001 is currently in phase 1 of the clinical trial. The company has a pipeline of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.
Key facts about ImmuneOncia
- Founded Year: 2016
- Location: Seongnam-si (South Korea)
- Stage: Public
- Total Funding till date: $60.5M
- Employee Count: 20 as on Jun 30, 2026
- Investors: E&Investment, LB Investment and 7 Others
- Latest Funding Round: Series B, Jan 17, 2022, $*****
- Highlight: Public
_1591591065079.png?format=webp&height=120&width=120){kind=logo}
5. RIDI
RIDI Corporation is a South Korea-based e-reading services company. It operates Ridibooks e-book store and provides PAPER PRO, an e-book terminal. It provides reading experiences through e-book app. Users can download the e-book files. Available for Ridibooks PAPER PRO, iOS, Android, Windows and Mac OS.
Key facts about RIDI
- Founded Year: 2008
- Location: Seoul (South Korea)
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $159M
- Employee Count: 317 as on Jun 30, 2026
- Investors: GIC, Shinhan Venture Investment and 13 Others
- Latest Funding Round: Series C, Jan 25, 2022, $*****
- Highlight: Editors' Pick
S&S Investment's Year-on-Year Investment Trends
S&S Investment has invested in 27 companies over the last 4 years, with an average of 1 new investment annually in the last 3 years. In 2025, it made 2 investments, while as of Aug 2026, it has made 2 investments in this year. Its most recent first time investment was in aweXome Ray and most recent follow-on round was in Pinetree Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 2 | 0 | 2 |
2025 | 1 | 1 | 2 |
2024 | 1 | 0 | 1 |
2023 | 1 | 0 | 1 |
2022 | 2 | 0 | 2 |
S&S Investment's Investments by Stage
S&S Investment has made 4 investments in Series B stage with an average round size of $16.8M and 3 investments in Series A stage with an average round size of $10.6M.Stage of entry | No. of Investments |
|---|---|
Series B | 4 |
Series A | 3 |
Note: We have considered here, only first round of investments
S&S Investment's Investments by Sector
S&S Investment has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, Environment Tech, High Tech and Sustainability Tech. Notably, it has invested in 20 Tech companies, 15 Enterprise (B2B) companies, 9 Software companies and at least 8 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 3 |
Enterprise Applications | 2 |
Environment Tech | 2 |
High Tech | 2 |
Sustainability Tech | 2 |
Others | 5 |
Note: We have considered here, only first round of investments
S&S Investment's Investments by Geography
S&S Investment has made most investments in South Korea (5), followed by United States where it has made 2 investments.Country | No. of Investments |
|---|---|
South Korea | 5 |
United States | 2 |
Note: We have considered here, only first round of investments
S&S Investment's recent investments
S&S Investment has made 2 investments in 2026 so far - aweXome Ray and Buysell Standards (PIECE).Here are the most recent investments by S&S Investment:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Aug 10, 2026 | South Korea | Series B | 4074 | ||
Mar 11, 2026 | South Korea | Series A | 2982 | [+1] | |
Nov 14, 2025 | United States | Series B | 3921 | [+7] | |
Jul 14, 2025 | South Korea | Series B | 3217 | [+16] | |
Jul 30, 2024 | United States | Series A | 8160 | [+4] |
Unicorns in S&S Investment's Portfolio
S&S Investment has 1 unicorn in its portfolio - RIDI. The most recent unicorn in their portfolio is RIDI which became a unicorn in 2022, 4 years before S&S Investment first invested in it.Here is a list of unicorns in S&S Investment's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
49 | E-book store operator | 2008 | Seoul | Series C | cbkvcko |
IPOs and Publicly Listed companies in S&S Investment's Portfolio
2 of S&S Investment's portfolio companies have become public. ImmuneOncia got listed on the Korea Exchange (KRX), in May 2025 at marketcap of $189M and SimPlatform got listed on the Korea Exchange (KRX) at marketcap of $62.8M.Here are S&S Investment's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 19, 2025 | - | - | 9642 | |
Mar 21, 2025 | - | - | 7557 |
Acquired companies in S&S Investment's Portfolio
1 company from S&S Investment's portfolio has been acquired. The most recent acquisition was Phantom in Feb 2026 by Harbinger Motors for $*****.Here are S&S Investment's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 25, 2026 | - | - | 1021 |
Team profile of S&S Investment
S&S Investment has a team of 5 members including 5 Partners located in South Korea. S&S Investment's team does not sit on the board of any company as of now.Here is a list of all team members in S&S Investment:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | - | - | - | |
Partner | - | - | - | |
Partner | - | - | - | |
Partner | South Korea | - | - | |
Partner | - | - | - |
Co-investors of S&S Investment
Over the past 4 years, 60 investors have co-invested in S&S Investment's portfolio companies. This includes funds and angels.
- Invested before S&S Investment: DSC Investment, Samho Green Investment and 19 others have invested in rounds before S&S Investment. There is 1 company where DSC Investment has invested before S&S Investment and 1 company where Samho Green Investment has invested before S&S Investment.
- Top Co-investors of S&S Investment: 35 investors entered a company along with S&S Investment. These include investors like Industrial Bank of Korea (3 companies).
- Invested after S&S Investment: A total of 4 investors have invested in S&S Investment's portfolio after their investments. Top Investors include Weed Win Investment (1 company), STIC Ventures (1 company) and Smile Gate Investment (1 company).
Recent News related to S&S Investment
•
•
•
Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degraders in Oncologyintelligence360•Nov 14, 2025•Gauss, Sj Invest Online, S&S Investment, Pinetree Therapeutics and 8 others
•
•
AMO succeeded in attracting KRW 14.4 billion in Pre-IPOZeroTwoOne Media•Sep 06, 2023•AIMMO, Envester, Korea Investment Holdings, Sumitomo Mitsui DS Asset Management and 2 others
